PlainRecalls
FDA Drug Moderate Class II Terminated

Docetaxel injection concentrate, 20 mg/mL, 1 mL vial, Rx only, Winthrop U.S. a business of Sanofi-Aventis U.S. LLC., NDC 0955-1020-01

Reported: May 9, 2018 Initiated: April 27, 2018 #D-0804-2018

Product Description

Docetaxel injection concentrate, 20 mg/mL, 1 mL vial, Rx only, Winthrop U.S. a business of Sanofi-Aventis U.S. LLC., NDC 0955-1020-01

Reason for Recall

Superpotent drug: over-concentrated vials of Docetaxel injection concentrate 20 mg/mL may have been distributed.

Details

Recalling Firm
Sanofi-Aventis U.S. LLC
Units Affected
19580 vials
Distribution
US nationwide
Location
Bridgewater, NJ

Frequently Asked Questions

What product was recalled?
Docetaxel injection concentrate, 20 mg/mL, 1 mL vial, Rx only, Winthrop U.S. a business of Sanofi-Aventis U.S. LLC., NDC 0955-1020-01. Recalled by Sanofi-Aventis U.S. LLC. Units affected: 19580 vials.
Why was this product recalled?
Superpotent drug: over-concentrated vials of Docetaxel injection concentrate 20 mg/mL may have been distributed.
Which agency issued this recall?
This recall was issued by the FDA Drug on May 9, 2018. Severity: Moderate. Recall number: D-0804-2018.